Ringworm Bush for Fungal Skin Infections

This is the claim ringworm bush is named for, in language after language, and it is the one claim with an actual, if imperfect, body of human evidence behind it. That combination — famous claim, real but incomplete human data — is rare enough on this site to be worth taking seriously rather than either dismissing as "just folklore" or inflating into "clinically proven." This page does the first careful read of that human evidence anyone has put in front of a general reader, alongside the laboratory work that explains why the traditional preparation might plausibly work at all.

Table of Contents

  1. What Ringworm and Tinea Actually Are
  2. Proposed Mechanism
  3. Laboratory Evidence, and the Arithmetic Against Pharmaceutical Standards
  4. Animal Evidence
  5. Human Evidence: Three Studies, Three Different Limitations
  6. Malassezia, Tinea Versicolor and a Shared Drug Target
  7. Topical Application and Why the Usual Arithmetic Objection Weakens
  8. The Cassia/Senna Nomenclature Problem for Self-Directed Searching
  9. How This Compares With Proven Antifungal Drugs
  10. What Is Not Known
  11. Key Research Papers
  12. Connections

What Ringworm and Tinea Actually Are

Ringworm is not a worm. It is a superficial fungal infection of the outer, dead layer of skin (or hair, or nail), caused by a group of fungi called dermatophytes that specifically digest keratin. The name "ring" describes the classic expanding, clearing-centre lesion, not the organism. Depending on the site, the same family of organisms produces tinea corporis (body ringworm), tinea pedis (athlete's foot), tinea cruris (jock itch), tinea capitis (scalp ringworm) and tinea unguium (nail fungus, onychomycosis). Trichophyton rubrum, Trichophyton mentagrophytes, Trichophyton tonsurans, Microsporum canis and Epidermophyton floccosum account for most cases worldwide.

Two other conditions get folded into "ringworm" in casual conversation and are worth separating cleanly, because they matter to the evidence below. Tinea versicolor (pityriasis versicolor) is not caused by a dermatophyte at all — it is caused by Malassezia, a yeast that lives on everyone's skin and occasionally overgrows, producing pale or tan patches, most often on the trunk. Tinea imbricata is a specific, geographically restricted dermatophyte infection caused by Trichophyton concentricum, endemic to parts of the Pacific, Southeast Asia and Central/South America, that produces a distinctive concentric, overlapping-scale pattern and behaves more stubbornly than ordinary ringworm. It matters below because the single best human study of ringworm bush was conducted specifically on tinea imbricata, not on garden-variety tinea corporis.

For general background on these conditions see Ringworm, Athlete's Foot, Tinea Versicolor and Fungal Infections generally.

Proposed Mechanism

Ringworm bush leaves are dominated chemically by anthraquinones — chrysophanol, aloe-emodin, rhein and emodin are the four named compounds, alongside flavonoids (chiefly kaempferol and its glycosides) and tannins. Anthraquinones are lipophilic ring structures that partition into fatty membranes. In laboratory studies of dermatophytes, the proposed mechanism is that these compounds insert into and disrupt the fungal cell membrane, interfere with membrane-bound enzyme systems, and impair hyphal growth, with some evidence of light-dependent reactive-oxygen generation adding a second stress on the fungal cell. This is a blunt, general-purpose membrane-toxicity mechanism, not a precise single-enzyme target — a real contrast with the pharmaceutical antifungals discussed below, which hit one named enzyme apiece.

A 2024 study went a step further and asked whether ringworm bush compounds might, computationally, resemble the pharmaceutical mechanism after all. Molecular docking of the plant's major lipid-soluble compounds against lanosterol 14-alpha-demethylase — the fungal enzyme that azole antifungal drugs (clotrimazole, fluconazole, ketoconazole) block — found plausible binding, with stearidonic acid showing the best predicted affinity. That is a computational prediction, not a demonstrated functional inhibition of the enzyme, and it should be read as exactly that: a plausible additional mechanism worth testing directly, not a confirmed one (Saptarini et al., 2024).

Laboratory Evidence, and the Arithmetic Against Pharmaceutical Standards

The in-vitro record is the plant's deepest evidence base, and it is genuinely large and repeated across decades and continents: French pharmacognosy groups in the early 1980s, Indian groups in 1990, Malaysian groups through the 1990s and 2000s, Philippine groups in the early 2000s, and a steady stream of Indonesian, Nigerian and Cameroonian work since — all report activity against dermatophytes, Candida albicans, or both, from leaf extracts (Fuzellier et al., 1982; Palanichamy & Nagarajan, 1990; Ibrahim & Osman, 1995; Somchit et al., 2003; Villaseñor et al., 2002).

One of the few studies to set the plant's activity directly beside a pharmaceutical reference gives numbers worth printing rather than waving at. Crockett and colleagues, screening the plant as a candidate for opportunistic infections in AIDS patients, measured minimum inhibitory and (fungicidal/bactericidal) concentrations for a water extract against E. coli and Candida albicans, alongside chloramphenicol and amphotericin B as reference standards:

Do the arithmetic, because it is more informative than either citing this as "confirmed activity" or ignoring it. 1.6 mg/mL is 1,600 µg/mL. Divided by chloramphenicol's 2 µg/mL, the crude extract is roughly 800 times weaker, milligram for milligram, than a standard antibacterial drug. Against Candida, 390 µg/mL versus amphotericin B's 0.58 µg/mL is roughly 670 times weaker. Both gaps are large, and a crude extract diluted 800-fold against a purified, optimised pharmaceutical is exactly the shape of gap the site's other herb pages have found for essential-oil and root-extract claims measured the same way — a real laboratory signal, a long way from drug-grade potency by weight (Crockett et al., 1992).

That gap matters differently for a systemic claim than for a topical one, which is the subject of its own section below.

Animal Evidence

Animal data specific to dermatophyte infection are thin. Older guinea-pig studies of experimentally infected animals reported reduced lesion severity with Cassia alata preparations, consistent with the in-vitro direction of effect, but this is a small and dated literature, not a systematic modern animal-trial base. Most of the animal work on this plant, discussed on the other three Benefits pages, concerns laxative pharmacology, anti-inflammatory screening and antidiabetic mechanism — not antifungal efficacy. The dermatophyte claim rests much more heavily on in-vitro work and the human studies below than on an animal-model literature.

Human Evidence: Three Studies, Three Different Limitations

Herbal antifungal pages on this site routinely have to report that human evidence is "thin" or "absent." Ringworm bush is a genuinely different case: there are three identifiable pieces of human evidence, spanning three decades, and each has a distinct and different limitation. Flattening them to a single verdict — either "proven" or "no human evidence" — would misrepresent all three. Here is what each one actually is.

1. The best-designed piece: a prospective, uncontrolled clinical study in an indigenous Philippine population (2020). Dermatologists from the University of the Philippines–Philippine General Hospital worked with the T'boli tribe of Southern Mindanao, where tinea imbricata — the concentric-pattern dermatophytosis described above — is endemic and community-prepared Senna alata leaf decoction is already the anecdotal treatment of choice. Twenty patients applied the decoction for four weeks. The investigators used real instruments: a pruritus visual-analogue scale, photographic disease-severity scoring by two assessors (with a stated inter-rater agreement, Cohen's kappa = 0.6, "moderate"), and potassium hydroxide (KOH) microscopy of skin scrapings — an objective mycology test, not just a look at the rash.

The results are genuinely mixed in an informative way. Ninety-five per cent of patients had a significant drop in itch (mean VAS decrease 4.05, P < .0001), and disease-severity scores improved significantly (P ≤ .05). But only 40 per cent converted to a negative KOH test — meaning most patients who felt and looked substantially better still had detectable fungal elements on microscopy at four weeks. No adverse events were recorded. There was no control or placebo arm, so natural waxing-and-waning of a chronic dermatophytosis cannot be excluded, and the authors' own conclusion calls for "larger clinical trials establishing its efficacy, effectiveness and safety profile" — not a claim of proof. Read plainly: this is real, prospectively measured, symptom-level improvement in a genuine indigenous-medicine setting, alongside an honestly reported mycological cure rate that undercuts the more impressive-looking symptom numbers (Eusebio-Alpapara et al., 2020, Mycoses).

2. A study that is often cited as "human evidence" but is not a treatment trial: a Nigerian schoolchildren survey (2009). Researchers in Cross River State, Nigeria, screened 840 primary-school pupils and found 68 (8.1 per cent) infected with dermatophytosis, most commonly Trichophyton tonsurans and Microsporum soudanense. They then tested the organisms isolated from those infected children for in-vitro susceptibility to Senna alata and a second local plant, alongside griseofulvin and clotrimazole, and reported the clinical isolates were more sensitive to the plant extracts than to the pharmaceutical comparators in that assay. This is valuable data — testing organisms freshly isolated from real infected patients is more clinically relevant than testing a reference laboratory strain — but no child in this study was treated with the plant. It is a susceptibility-of-clinical-isolates study wearing the shape of a treatment study when summarised loosely, and this page declines to describe it as one (Eja et al., 2009).

3. The oldest and least verifiable: a 1994 report of a "10-year human study." An Indian pharmacology group reported what its own abstract calls "the therapeutic efficacy of Cassia alata leaf extract against Pityriasis versicolor... reported for the first time involving humans," describing a ten-year period of use and stating the extract "has no side-effects." The abstract gives no sample size, no control group, no blinding, and no statistical test — it is a short report, of the kind common in that era's pharmacology journals, and there is no fuller methodology available to check the claim against. This page will not describe it as either a clinical trial or as worthless: it is old, positive, and its methodology cannot be verified from the available record, which is a specific and different limitation from either of the two studies above (Damodaran & Venkataraman, 1994).

What none of the three is: a randomised, controlled, blinded trial. None could easily be blinded in the first place — a leaf decoction announces itself by smell, colour and texture, so comparing it against a genuinely indistinguishable placebo is a real methodological obstacle for this whole category of remedy, not a excuse for why it has not been attempted. There is a subtler point worth naming, too: this plant's own name, across unrelated language families, asserts the outcome (see the Names and Identification section on the main page for the full list — "ringworm bush," dadmurdan, dadmari). In an unblinded study, a patient and an assessor who both already know the plant's reputation are exactly the conditions in which a subjective measure like a pruritus VAS is most likely to move even without full mycological cure — which is one plausible reading of why the Philippine study's symptom scores (95 per cent improved) so substantially outran its KOH clearance rate (40 per cent). This does not mean the itch relief was imaginary; it means the size of the gap between the two endpoints is itself informative, and a future trial with an inert-looking comparator decoction and blinded KOH reading would settle it.

Malassezia, Tinea Versicolor and a Shared Drug Target

Malassezia furfur, the yeast behind tinea (pityriasis) versicolor, is not a dermatophyte and is a biologically different target from everything discussed above. The 2024 docking study mentioned earlier was designed specifically around this organism: ethyl acetate and n-hexane leaf fractions showed concentration-dependent inhibition of M. furfur in disc-diffusion testing, five major compounds were identified by LC-MS/MS, and computational docking suggested the n-hexane fraction's compounds could plausibly bind lanosterol 14-alpha-demethylase — the same enzyme pharmaceutical azoles inhibit (Saptarini et al., 2024). This is consistent with, and gives a specific modern mechanism to, the much older Damodaran report of use against Pityriasis versicolor discussed above. It remains an in-vitro and computational finding; nobody has run a versicolor-specific human trial of this plant analogous to the tinea imbricata study. See Tinea Versicolor and Seborrheic Dermatitis, a related Malassezia-associated condition, for the clinical picture.

Topical Application and Why the Usual Arithmetic Objection Weakens

The standard way this site deflates an in-vitro antimicrobial finding is to ask how much of the plant a person would have to consume to reach the inhibitory concentration in their bloodstream — and the answer is usually an absurd quantity, because a systemic dose has to survive absorption, first-pass liver metabolism and dilution across roughly 42 litres of body water before it reaches a target tissue.

That calculation does not apply cleanly here, and it is worth saying so plainly rather than repeating the usual dismissal out of habit. The traditional and endorsed use of ringworm bush is not systemic at all — crushed leaf or extract is rubbed directly onto the skin surface where the fungus lives. A concentrated paste or extract applied topically can plausibly deliver a local concentration in the same rough order of magnitude as the milligram-per-millilitre MICs measured in the lab, without needing to survive digestion, first-pass metabolism, or systemic dilution at all. This is the same logic the site has applied to a swallowed astringent acting inside the gut lumen: when the site of action and the site of application are the same compartment, the usual "impossible blood concentration" objection loses most of its force.

What this does not establish is efficacy against an established infection at depth in skin or under a nail plate, where penetration becomes the limiting factor rather than concentration at the surface. It is also not an argument for internal use, where the original systemic-dilution objection returns in full, and where a second and more serious problem — the plant's own laxative chemistry, covered on the laxative and anthraquinone page — takes over as the reason not to swallow it.

The Cassia/Senna Nomenclature Problem for Self-Directed Searching

Anyone who tries to verify the claims on this page by searching the literature independently should know that this species has been indexed under two different genus names across the research record, and the split is not evenly distributed across time. Nearly all of the antifungal literature published before roughly 2010 — including the two oldest and most influential papers on this page, the 1982 French study and the 1990 Indian study — is indexed as Cassia alata. More recent work increasingly uses Senna alata, reflecting the taxonomic revision that moved most of the old genus Cassia into Senna (covered in full on the main page's Names and Identification section). A search restricted to only one of the two names will silently miss a meaningful fraction of the record. Every citation on this page was checked against both name forms for exactly this reason, and every linked search below is scoped to the plant's own literature rather than the wider genus, to avoid pulling in results about the unrelated laxative senna or other Senna/Cassia species that share shelf space and search terms with this one.

How This Compares With Proven Antifungal Drugs

Topical terbinafine 1% and clotrimazole 1% are inexpensive, sold over the counter almost everywhere, and supported by a large randomised-trial literature with mycological cure rates commonly in the 70–90 per cent range for tinea pedis and tinea corporis in a two-to-four-week course — a materially higher and better-verified bar than the 40 per cent KOH clearance seen in the one prospective human study of ringworm bush discussed above (comparative trial literature). Where a proven, cheap, over-the-counter drug is available, it remains the better-evidenced choice for a straightforward case. Ringworm bush's realistic place is where it has always occupied one: a free, locally available, low-risk option in a setting where pharmaceutical antifungals are expensive, hard to access, or simply not part of the household's practice — which is precisely the setting the Philippine tinea imbricata study was conducted in. Scalp ringworm (tinea capitis) and nail fungus (onychomycosis) need oral prescription antifungals regardless of what topical product is used, herbal or pharmaceutical, because no cream reliably penetrates a hair follicle or a nail plate.

What Is Not Known

  1. No randomised, controlled, blinded human trial exists for any dermatophyte or Malassezia indication. All three human data points above have a specific, named limitation; none is negative, but none is confirmatory either.
  2. No dose-finding work. The Philippine study used a community-prepared decoction of unspecified concentration; no study has varied concentration or frequency to find an optimum.
  3. No standardisation marker for a topical antifungal preparation, so two batches of leaf paste or two commercial lotions cannot be compared for potency against each other.
  4. No trial has compared ringworm bush head-to-head against a pharmaceutical antifungal in the same patients under the same conditions; the comparison in this article is between separate studies with different designs, which is weaker than a direct trial.
  5. No penetration data for nail or hair-follicle involvement, where the topical antifungal question is entirely different from skin-surface application.
  6. The lanosterol demethylase docking result is computational, not a demonstrated functional enzyme inhibition — a real and specific gap between an in-silico prediction and a proven mechanism.

Key Research Papers

Every link below is a live, pre-validated PubMed search scoped to this species specifically, checked before publication to confirm it returns the intended paper rather than an empty result or an unrelated Cassia/Senna species.

  1. Eusebio-Alpapara KMV, Dofitas BL, Balita-Crisostomo CLA, et al. "Senna (Cassia) alata (Linn.) Roxb. leaf decoction as a treatment for tinea imbricata in an indigenous tribe in Southern Philippines." Mycoses, 2020 — the single best human study, prospective, N=20, with objective and subjective endpoints.
  2. Eja ME, Arikpo GE, Enyi-Idoh KH, et al. "Efficacy of local herbal therapy in the management of dermatophytosis among primary school children in Cross River State, South-south Nigeria." African Journal of Medicine and Medical Sciences, 2009 — prevalence survey plus in-vitro susceptibility of clinical isolates, not a treatment trial.
  3. Damodaran S, Venkataraman S. "A study on the therapeutic efficacy of Cassia alata, Linn. leaf extract against Pityriasis versicolor." Journal of Ethnopharmacology, 1994 — the oldest human report; methodology not verifiable from the abstract.
  4. Saptarini NM, Mustarichie R, Hasanuddin S, Corpuz MJT. "Cassia alata L.: A Study of Antifungal Activity against Malassezia furfur, Identification of Major Compounds, and Molecular Docking to Lanosterol 14-Alpha Demethylase." Pharmaceuticals, 2024.
  5. Crockett CO, Guede-Guina F, Pugh D, et al. "Cassia alata and the preclinical search for therapeutic agents for the treatment of opportunistic infections in AIDS patients." Cellular and Molecular Biology, 1992 — the source of the MIC arithmetic above.
  6. Palanichamy S, Nagarajan S. "Antifungal activity of Cassia alata leaf extract." Journal of Ethnopharmacology, 1990.
  7. Fuzellier MC, Mortier F, Lectard P. "Antifungal activity of Cassia alata L." Annales Pharmaceutiques Françaises, 1982.
  8. Ibrahim D, Osman H. "Antimicrobial activity of Cassia alata from Malaysia." Journal of Ethnopharmacology, 1995.
  9. Villaseñor IM, et al. "Bioactivity studies on Cassia alata Linn. leaf extracts." Phytotherapy Research, 2002.
  10. Somchit MN, et al. "In vitro antimicrobial activity of ethanol and water extracts of Cassia alata." Journal of Ethnopharmacology, 2003.
  11. Ajose FO. "Some Nigerian plants of dermatologic importance." International Journal of Dermatology, 2007 — clinic-based survey of herbal use, including this plant, among dermatology patients.
  12. Oladeji OS, Adelowo FE, Oluyori AP, Bankole DT. "Ethnobotanical Description and Biological Activities of Senna alata." Evidence-Based Complementary and Alternative Medicine, 2020 — review.
  13. Colin MN, Claudiana NSE, Kaffah AU, et al. "Review on Cassia alata Bioactive Compounds: In silico, in vitro, and in vivo Studies." Drug Design, Development and Therapy, 2024 — notes explicitly that dosage-form evaluation lags behind the antifungal, antidiabetic and antiviral screening literature.
  14. Comparative randomised-trial literature on topical terbinafine and clotrimazole for tinea pedis — the pharmaceutical benchmark referenced above.
  15. Trichophyton concentricum and tinea imbricata epidemiology — background on the specific infection the best human study addressed.

Connections

Back to Table of Contents